154 related articles for article (PubMed ID: 36788919)
1. Molecular Basis of Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.
Surjan RCT; de Lima TM; de Souza HP; Machado MCC; Ardengh JC
Cureus; 2023 Jan; 15(1):e33750. PubMed ID: 36788919
[TBL] [Abstract][Full Text] [Related]
2. A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.
Surjan RC; Dos Santos ES; Basseres T; Makdissi FF; Machado MA
Am J Case Rep; 2017 Mar; 18():234-241. PubMed ID: 28270654
[TBL] [Abstract][Full Text] [Related]
3. Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review.
Cho J; Chen JCY; Paludo J; Conboy EE; Lanpher BC; Alberts SR; Halfdanarson TR
J Gastrointest Oncol; 2019 Jun; 10(3):582-588. PubMed ID: 31183212
[TBL] [Abstract][Full Text] [Related]
4. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.
Chapuy CI; Sahai I; Sharma R; Zhu AX; Kozyreva ON
Oncologist; 2016 Apr; 21(4):514-20. PubMed ID: 26975868
[TBL] [Abstract][Full Text] [Related]
5. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
6. [Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma].
Berger C; Dimant P; Hermida L; Paulin F; Pereyra M; Tejo M
Medicina (B Aires); 2012; 72(5):425-7. PubMed ID: 23089120
[TBL] [Abstract][Full Text] [Related]
7. Hyperammonemic Encephalopathy Mimicking Ornithine Transcarbamylase Deficiency in Fibrolamellar Hepatocellular Carcinoma: Successful Treatment with Continuous Venovenous Hemofiltration and Ammonia Scavengers.
Lee JS; Jin HY; Ko JM; Kim SH; Han N; Park BK; Park M; Park HJ; Lee JA
Cancer Res Treat; 2021 Jan; 53(1):283-288. PubMed ID: 32898940
[TBL] [Abstract][Full Text] [Related]
8. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
[TBL] [Abstract][Full Text] [Related]
9. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
[TBL] [Abstract][Full Text] [Related]
10. Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.
Sethi S; Tageja N; Singh J; Arabi H; Dave M; Badheka A; Revankar S
Am J Med Sci; 2009 Dec; 338(6):522-4. PubMed ID: 20010160
[TBL] [Abstract][Full Text] [Related]
11. Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review.
Ahmed A; Ata F; Gaber M; Petkar M; Mahfouz A; Schirmacher P; Musa S; Hashim A
Curr Probl Cancer; 2022 Jun; 46(3):100847. PubMed ID: 35276469
[TBL] [Abstract][Full Text] [Related]
12. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
13. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
14. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
15. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma.
Patonai A; Erdélyi-Belle B; Korompay A; Somorácz A; Straub BK; Schirmacher P; Kovalszky I; Lotz G; Kiss A; Schaff Z
Virchows Arch; 2011 Jun; 458(6):679-88. PubMed ID: 21503766
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.
Simon EP; Freije CA; Farber BA; Lalazar G; Darcy DG; Honeyman JN; Chiaroni-Clarke R; Dill BD; Molina H; Bhanot UK; La Quaglia MP; Rosenberg BR; Simon SM
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):E5916-25. PubMed ID: 26489647
[TBL] [Abstract][Full Text] [Related]
17. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract][Full Text] [Related]
18. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
[TBL] [Abstract][Full Text] [Related]
19.
Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
[TBL] [Abstract][Full Text] [Related]
20. Fibrolamellar hepatocellular carcinoma mimicking ornithine transcarbamylase deficiency.
Sulaiman RA; Geberhiwot T
JIMD Rep; 2014; 16():47-50. PubMed ID: 24997132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
